Scientific INformAtion for Policy Support in Europe
Sinapse home page

Library of scientific opinion & advice > Document description

Should you like to save, print or communicate the information related to this document, you can download this description page in a word processor compatible format.


TITLE The development of new SARS vaccines and therapies   sarsvac_en.pdf (3.51 MB)
Document ID LIB88
Document type EC RTD Programmes projects / results
Issue date 08/03/2005
Document reference SARSVAC
Original language of the document English
Document produced by EC-Research and Innovation DG organisation visiting card
Document requested by EC-Research and Innovation DG organisation visiting card
Scientific domains
Policy domains
  • Health


Short description  SARSVAC will provide an integrated strategy for developing effective vaccines and therapeutic treatments for use in controlling SARS outbreaks. In order to expedite the process, a three-pronged approach will be adopted:
· Preparation of an inactivated vaccine using methods that have been successfully employed in the development of other coronavirus vaccines
· Development of a recombinant vaccine based on SARS virus-like particles (VLP) which are non-infectious but will stimulate the production of antibodies and immune T-cells
· Preparation of therapeutic antibodies against SARS that can be used for passive immunotherapy
Abstract (focusing on the key recommendations)  In 2003, a SARS (severe acute respiratory syndrome) outbreak emerged in southern China. Caused by a novel coronavirus that is believed to have jumped from an animal host to humans, the infection spread rapidly to other countries through international travel. In total, 28 countries reported SARS cases and the worldwide death rate from SARS was around 10% of all cases reported. The overall economic ...

[View the complete abstract]
Full Text

Please wait...
Sinapse is currently processing your request.

This might take a few moments before the page can be displayed.